Up 755% Over the Past 3 Years, Can This Biotech Be Stopped?

Regeneron Pharmaceuticals (REGN 2.07%) has been on a tear, up more than 750% over the past three years.

Much of that success has to do with one drug in the company's arsenal: Eylea, to treat macular degeneration. Despite going head-to-head against an established player in Roche's Lucentis, Eylea has done remarkably well, producing U.S. sales of more than $400 million in the fourth quarter of last year. This year, Regeneron is guiding for U.S. sales of $1.7 billion to $1.8 billion.

The rest of Regeneron's value can mostly be attributed to the pipeline it's building through a partnership with Sanofi (SNY -0.91%). Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss Regeneron and Sanofi's drugs that are on the market and pipeline, including alirocumab, their PCSK9 inhibitor that will compete against Amgen's (AMGN 11.82%) evolocumab if both drugs are approved.